Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note released on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Aptose Biosciences Stock Down 3.8 %

Shares of APTO stock opened at $0.38 on Tuesday. The business has a 50-day moving average price of $0.38 and a two-hundred day moving average price of $0.68. Aptose Biosciences has a 12-month low of $0.33 and a 12-month high of $3.32. The firm has a market cap of $6.93 million, a P/E ratio of -0.09 and a beta of 1.26.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.